How does The Genotype Network help M&A lawyers close Life Sciences transactions?

Strengthening Global M&A Support in Life Sciences

The Genotype Network (TGN) is a global alliance of leading Life Sciences Regulatory lawyers, purpose-built to support cross-border M&A transactions. TGN lawyers work closely with M&A teams around the world to provide specialist regulatory insight throughout the deal process.

In that context, Hanneke Later-Nijland, the founder of TGN, visited New York City during the IBA M&A week early June, in order to connect with international M&A lawyers.

Last year, TGN contributed to a €2.4 billion multi-jurisdictional transaction led by a US-based M&A team at a global law firm. Our deep industry knowledge — spanning jurisdictions including Austria, Germany, France, Italy, the UK, and The Netherlands — helped uncover key regulatory risks, ultimately enabling the client to negotiate a lower purchase price.

We’re excited to continue expanding our presence in key jurisdictions and look forward to supporting M&A teams — both in execution and in competitive pitch processes — with our regulatory expertise in pharma, biotech, and broader life sciences.

For more information, download our One-Pager for M&A lawyers here!

The-Genotype-Network-One-pager-for-MA-lawyers.pdf

Download PDF • 284KB